Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186663 | 0.94 | HRH3 (0.64) | HRH3ESR1ESR2PKMLMNA | |
| SCHEMBL25903917 | 0.85 | HRH3 (0.60) | HRH3ESR1ESR2PKMLMNA | |
| SCHEMBL5100248 | 0.84 | HRH3 (0.61) | HRH3ESR1ESR2 | |
| SCHEMBL1267241 | 0.83 | HRH3 (0.70) | HRH3ESR1ESR2PKMLMNA | |
| SCHEMBL3171545 | 0.82 | HRH3 (0.57) | HRH3ESR1ESR2 | |
| SCHEMBL3187407 | 0.81 | HRH3 (0.55) | HRH3ESR1ESR2PKMLMNA | |
| SCHEMBL3184675 | 0.80 | HRH3 (0.72) | HRH3ESR1ESR2 | |
| SCHEMBL3177946 | 0.80 | ESR2 (0.62) | HRH3ESR1ESR2 | |
| SCHEMBL3190691 | 0.79 | ESR2 (0.64) | HRH3ESR1ESR2PKMLMNA | |
| SCHEMBL4434244 | 0.79 | HRH3 (0.53) | HRH3ESR1ESR2PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | HRH3 2402/4885ESR1 3006/4885ESR2 1537/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | HRH3 2620/4885ESR1 3024/4885ESR2 1445/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | HRH3 2402/4885ESR1 3006/4885ESR2 1537/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | HRH3 2620/4885ESR1 3024/4885ESR2 1445/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | HRH3 2620/4885ESR1 3024/4885ESR2 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.